The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse

Neurodegeneration

Volumn 5, Issue 4, 1996, Pages 299-312

  German, Dwight C ^a   Nelson, Eric L ^a   Liang, Chang Lin ^a   Speciale, Samuel G ^a   Sinton, Christopher M ^a   Sonsalla, Patricia K ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Computer imaging; Immunohistochemical staining; Midbrain dopaminergic neurons; Mouse; MPP+; MPTP; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; NEUROTOXIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESENCEPHALON; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 0030499311     PISSN: 10558330     EISSN: None     Source Type: Journal    
DOI: 10.1006/neur.1996.0041     Document Type: Article

References (50)

1. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94:239-247
2. Arai N, Misugi K, Goshima Y, Misu Y (1990) Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated C57 black mouse model for parkinsonism. Brain Res 515:57-63
3. Bogerts B, Hantsch J, Herzer M (1983) A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psychiat 18:951-969
4. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin I (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta ofthe substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546-4550
5. Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH (1987) Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Life Sci 40:193-202
6. Elsworth JD, Deutch AY, Redmond DE, Sladek JR, Roth RH (1990) MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Res 513:320-324
7. Fallon J, Moore RY (1978) Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J Comp Neurol 180:545-580
8. German DC, Manaye KF (1993) Midbrain dopaminergic neurons (nuclei A8, A9 and A10): Three-dimensional reconstruction in the rat. J Comp Neurol 331:297-309
9. German DC, Schlusselberg DS, Woodward DJ (1983) Three-dimensional reconstruction of midbrain dopaminergic neuronal populations: from mouse to man. J Neural Transm 57:243-254
10. 28k-containing cells. Ann NY Acad Sci 648:42-62
11. German DC, Dubach M, Askari S, Speciale SG, Bowden DM (1988) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca Fascicularis: Which midbrain dopaminergic neurons are lost? Neurosci 24:161-174
12. German DC, Manaye KF, Smith WK, Woodward DJ, Saper CB (1989) Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann Neurol 26:507-514
13. Giovanni A, Sieber B-A, Heikkila RE, Sonsalla PK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Thera 257:691-697
14. Hallman H, Lange J, Olson L, Stromberg I, Jonsson G (1985) Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. J Neurochem 44:117-127
15. Hassler R (1939) Zur pathologischen anatomie des senilen und des parkinsonistichen tremor. J Psychol Neurol 49:13-55
16. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 224:1451-1453
17. + within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neurosci 40:133-158
18. 28k-like immunoreactivity in catecholaminergic cell groups of the human midbrain: normal distribution and distribution in Parkinson's disease. Neurodegen 1:83-93
19. Hornykiewicz O (1979) Brain dopamine in Parkinson's disease and other neurological disturbances. In Horn AS, Korf J, Westerink BHC (eds), The Neurobiology of Dopamine. New York, Academic Press, pp. 633-654
20. 2 receptor messenger RNAs are differentially expressed in limbic-and motor-related subpopulations of human mesencephalic neurons. Neurosci 63:357-362
21. Imai H, Nakamura T, Endo K, Narabayasbi H (1988) Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology. Brain Res 474:327-332
22. Irwin I, Delanney LE, Langston JW (1993) MPTP and aging studies in the C57BL/6 mouse. Adv Neurol 60:197-206
23. + in the substantia nigra: a key to neurotoxicity? Life Sci 36:207-212
24. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177
25. Konigsmark BW (1970) Methods for the counting of neurons. In Nauta WJH, Ebbeson SOE (eds), Contemporary Research Methods in Neuroanatomy. Springer, New York, pp. 315-380
26. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
27. Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292:390-394
28. Lavoie B, Parent A (1991) Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Neuro Rep 2:601-604
29. 28k and calretinin. Neurosci, in press
30. 28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 5:313-318
31. Lindvall O, Bjorklund A (1974) The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method. Acta Physiol Scand [Suppl] 412:1-48
32. Lorang D, Amara SG, Simerly RB (1994) Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14:4903-4914
33. Mori S, Fujitake J, Kuno S, Sano Y (1988) Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies. Neurosci Lett 90:57-62
34. Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M, Przedborski S (1994) Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/b1 and CD-1 mice. Exp Neurol 126:195-204.
35. Perry TL, Yong VW, Jones K, Wall RA, Clavier RM, Foulks JG, Wright JM (1985) Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. Neurosci Lett 58:321-326
36. Saitoh T, Nijima K, Mizuno Y (1987) Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice. J Neurol Sci 77:229-235
37. Sanghera MK, Manaye KF, Liang C-L, Iacopino AM, Bannon MJ, German DC (1994) Low dopamine transporter mRNA levels in midbrain regions containing calbindin. NeuroRep 5:1641-1644
38. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328
39. Schneider JS, Markham CH (1986) Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat: Tyrosine hydroxylase immunohistochemistry. Brain Res 373:258-267
40. Shimada S, Kitayama S, Walther D, Uhl G (1992) Dopamine transporter mRNA: Dense expression in ventral midbrain neurons. Mol Brain Res 13:359-362
41. Shultz W, Scarnati E, Sundstrom E, Romo R (1989) Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions. Neurosci 31:219-230
42. Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. European J Pharmacol 129:339-345
43. Sonsalla PK, Youngster SK, Kindt MV, Heikkila RE (1987) Characteristics of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J Pharmacol Exp Thera 242:850-857
44. Sundstrom E, Stromberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405:26-38
45. Sundstrom E, Luthman J, Goldstein M, Jonsson G (1988) Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57BL/6 mice. Brain Res Bull 21:257-263
46. Swanson LW (1982) The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9:321-353
47. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT, Overbeek PA (1991) FVB/N: An inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci 88:2065-2069
48. Ungerstedt U (1971) Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand [Suppl] 367:1-48
49. Varastet M, Riche D, Maziere M, Hantraye P (1994) Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neurosci 63:47-56
50. 28k-Brain Res 526:303-307